Clinical trials
Phase 2 Lipid Metabolism Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2020 | 3 |
| 2022 | 3 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Akcea Therapeutics | 3 |
| Kastle Therapeutics, LLC | 3 |
| Caliway Biopharmaceuticals Co., Ltd. | 2 |
| Eli Lilly and Company | 2 |
| 89bio, Inc. | 1 |
| Alborz Medical University | 1 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Baylor College of Medicine | 1 |
| Catabasis Pharmaceuticals | 1 |
| Furiex Pharmaceuticals, Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lipid Metabolism Disorders | 21 |
| Dyslipidemias | 14 |
| Metabolic Diseases | 12 |
| Hyperlipidemias | 10 |
| Hypercholesterolemia | 7 |
| Hypertriglyceridemia | 5 |
| Genetic Diseases, Inborn | 4 |
| Hyperlipoproteinemias | 4 |
| Lipid Metabolism, Inborn Errors | 4 |
| Metabolism, Inborn Errors | 4 |
Trials
Showing 76 to 21 of 21. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.